Anesth Analg 2007;104:569-574
© 2007 International Anesthesia Research Society
doi: 10.1213/01.ane.0000248224.42707.48
ANESTHETIC PHARMACOLOGY
Sugammadex Reversal of Rocuronium-Induced Neuromuscular Blockade: A Comparison with NeostigmineGlycopyrrolate and EdrophoniumAtropine
Ozlem Sacan, MD,
Paul F. White, MD, PhD,
Burcu Tufanogullari, MD, and
Kevin Klein, MD
From Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas.
Address correspondence and reprint requests to Paul F. White, MD, PhD, Department of Anesthesiology and Pain Management; University of Texas Southwestern Medical Center at Dallas; 5161 Harry Hines Blvd., CS 2. 282, Dallas, TX 75390-9068. Address e-mail to paul.white{at}utsouthwestern.edu.
BACKGROUND: Sugammadex is a modified cyclodextrin compound, which encapsulates rocuronium to provide for a rapid reversal of residual neuromuscular blockade. We tested the hypothesis that sugammadex would provide for a more rapid reversal of a moderately profound residual rocuronium-induced blockade than the commonly used cholinesterase inhibitors, edrophonium and neostigmine.
METHODS: Sixty patients undergoing elective surgery procedures with a standardized desfluraneremifentanilrocuronium anesthetic technique received either sugammadex, 4 mg/kg IV (n = 20), edrophonium, 1 mg/kg IV and atropine, 10 µg/kg IV (n = 20), or neostigmine, 70 µg/kg IV and glycopyrrolate, 14 µg/kg IV (n = 20) for reversal of neuromuscular blockade at 15 min or longer after the last dose of rocuronium using acceleromyography to record the train-of-four (TOF) responses. Mean arterial blood pressure and heart rate values were recorded immediately before and for 30 min after reversal drug administration. Side effects were noted at discharge from the postanesthesia care unit.
RESULTS: The three groups were similar with respect to their demographic characteristics and total dosages of rocuronium prior to administering the study medication. Although the initial twitch heights (T1) at the time of reversal were similar in all three groups, the time to achieve TOF ratios of 0.7 and 0.9 were significantly shorter with sugammadex (71 ± 25 and 107 ± 61 s) than edrophonium (202 ± 171 and 331 ± 27 s) or neostigmine (625 ± 341 and 1044 ± 590 s). All patients in the sugammadex group achieved a TOF ratio of 0.9 5 min after reversal administration compared with none and 5% in the edrophonium and neostigmine groups, respectively. Heart rate values at 2 and 5 min after reversal were significantly higher in the neostigmine-glycopyrrolate group compared with that in sugammadex. Finally, the incidence of dry mouth was significantly reduced in the sugammadex group (5% vs 85% and 95% in the neostigmine and edrophonium groups, respectively).
CONCLUSION: Sugammadex, 4 mg/kg IV, more rapidly and effectively reversed residual neuromuscular blockade when compared with neostigmine (70 µg/kg IV) and edrophonium (1 mg/kg IV). Use of sugammadex was associated with less frequent dry mouth than that with the currently used reversal drug combinations.
This article has been cited by other articles:

|
 |

|
 |
 
P. F. White, B. Tufanogullari, O. Sacan, E. G. Pavlin, O. J. Viegas, H. S. Minkowitz, and M. E. Hudson
The Effect of Residual Neuromuscular Blockade on the Speed of Reversal with Sugammadex
Anesth. Analg.,
March 1, 2009;
108(3):
846 - 851.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. Staals, M. M. J. Snoeck, J. J. Driessen, E. A. Flockton, M. Heeringa, and J. M. Hunter
Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function
Br. J. Anaesth.,
October 1, 2008;
101(4):
492 - 497.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. Flockton, P. Mastronardi, J. M. Hunter, C. Gomar, R. K. Mirakhur, L. Aguilera, F. G. Giunta, C. Meistelman, and M. E. Prins
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine
Br. J. Anaesth.,
May 1, 2008;
100(5):
622 - 630.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Cammu, P. J. De Kam, I. Demeyer, M. Decoopman, P. A. M. Peeters, J. M. W. Smeets, and L. Foubert
Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers
Br. J. Anaesth.,
March 1, 2008;
100(3):
373 - 379.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. F. White, G. Hill, and A. Lenz
Where's the Fire?
Anesth. Analg.,
September 1, 2007;
105(3):
878 - 878.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. F. White, H. Kehlet, J. M. Neal, T. Schricker, D. B. Carr, F. Carli, and the Fast-Track Surgery Study Group
The Role of the Anesthesiologist in Fast-Track Surgery: From Multimodal Analgesia to Perioperative Medical Care
Anesth. Analg.,
June 1, 2007;
104(6):
1380 - 1396.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. D. Miller
Sugammadex: An Opportunity to Change the Practice of Anesthesiology?
Anesth. Analg.,
March 1, 2007;
104(3):
477 - 478.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Lenz, G. Hill, and P. F. White
Emergency Use of Sugammadex After Failure of Standard Reversal Drugs
Anesth. Analg.,
March 1, 2007;
104(3):
585 - 586.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|